T‑ALL is a difficult subtype that includes: acute lymphocytic leukemiathe most common childhood cancer. Although complete remission rates have improved, many survivors experience long-term effects from intensive chemotherapy.
Rapid determination of drug response allows clinicians to individualize treatment faster, reducing exposure to ineffective treatments and side effects. For these patients, quickly identifying the most effective treatment can be lifesaving.
“In pediatric malignancies, there is an urgent need for innovation in treatment selection,” he says. Luke Mace, DO; Mace, a pediatric oncologist at the Huntsman Cancer Institute and an associate professor of pediatrics in the United States, treats children with leukemia who could benefit from advances like μPharma’s. “Personalized treatment selection achieved in ‘real time’ will be part of the future of cancer treatment. μPharma represents an encouraging step in that direction. ”
In a study published in med, The scientists also demonstrated that μPharma accurately predicted response to two targeted therapies currently being studied for T-ALL, dasatinib and venetoclax, and uncovered a previously unrecognized association between drug response and key molecular markers of T-ALL.
